Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

NCT03121677 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Vaccine manufacturing has been suspended

Conditions

Follicular Lymphoma

Interventions

BIOLOGICAL: Personalized tumor vaccine
DRUG: Poly ICLC
BIOLOGICAL: Nivolumab
PROCEDURE: Peripheral blood draws
PROCEDURE: Leukapheresis
BIOLOGICAL: Rituximab
PROCEDURE: Biopsy

Sponsor

Washington University School of Medicine